aidsmeds postcasts

[Guest guest]

CROI Podcasts14th Conference on Retroviruses and Opportunistic InfectionsAIDSmeds.com Coverage of CROI 2007Los Angeles, CaliforniaFebruary 25-28, 2007The Plot Thickens: HIV Treatment Challenges (3/9/07) AIDSmeds founder Staley interviewed Dr. Calvin Cohen, research director of the Community Research Initiative of New England. They discussed Kaletra's possible lipoatrophy advantage to Sustiva; the CDC's new data showing a rise of HIV drug resistance in the newly infected; and HIVers dying more from non-AIDS-related cancers. Listen to the full interview:16 minutes (7.4MB mp3) Or part I about Kaletra's possible lipoatrophy advantage to Sustiva8.5 minutes (3.9MB mp3) Or part II about the CDC's new data showing a rise of HIV drug resistance in the newly infected:4 minutes (1.9MB mp3) Or part III about HIVers dying more from non-AIDS-related cancers:3.5 minutes (1.6MB mp3)The Skinny on Metabolic Complications (3/8/07) Staley also interviewed Dr. Kotler, chief of gastroenterology at St. Luke’s-Roosevelt Hospital in New York, and a longtime researcher of wasting, lipodystrophy, and metabolic problems in people with HIV. Kotler discusses TH-9507, an experimental drug for reducing fat around the gut; Fosamax helping with bone loss in HIVers; high-fat diets in people with HIV; and whether lipid-lowering drugs work well for HIVers. Listen to the full interview:21 minutes (9.7MB mp3) Or part I about TH-9507, an experimental drug for reducing fat around the gut:8 minutes (4MB mp3) Or part II about Fosamax helping with bone loss in HIVers:6 minutes (2.6MB mp3) Or part III about high-fat diets in people with HIV:2 minutes (1MB mp3)Or part IV about whether lipid-lowering drugs work well for HIVers:5 minutes (2.2MB mp3)What's New? Update on Experimental Agents (3/8/07) Dr. Calvin Cohen, research director of the Community Research Initiative of New England, discusses new drugs in the pipeline that might help treatment-experienced patients needing new options. Hear the latest news about Isentress and elvitegravir, two integrase inhibitor, maraviroc, a CCR5 inhibitor, and TMC-278, a new non-nuke. Listen to the full interview:14 minutes (6.5MB mp3) Or part I about Isentress, Merck's new integrase inhibitor:4 minutes (2MB mp3) Or part II about elvitegravir, Gilead's new integrase inhibitor:2 minutes (1MB mp3) Or part III about maraviroc, Pfizer's new CCR5 inhibitor:5 minutes (2.3MB mp3)Or part IV about TMC-278, Tibotec's new non-nuke:3 minutes (1.3MB mp3)

Our post-CROI conference interviews were generously sponsored by Abbott Laboratories.

AdvertisementSimplified HIV DosingFDA approved HIV medicationget the facts!www.oneHIVpill.com

One final CROI news story from AIDSmeds.comMarch 09, 2007

Study Finds Viread Advantages in Black PatientsAn analysis of two Gilead-sponsored studies suggests that black HIV-positive patients have a better chances of an undetectable viral load after 96 weeks using treatment regimens containing Viread compared to those containing the thymidine analogues Retrovir or Zerit.

At your request, you are subscribed as powertx@... to the following newsletter(s): Please remember to add news@... to your e-mail address book, so that these updates aren't blocked as spam.To change your subscription information and preferences, please visit list.poz.com//?p=preferencesTo stop receiving this newsletter, please visit list.poz.com//?p=unsubscribe

Copyright 2007 Smart + Strong, 500 Fifth Avenue, Suite 320, New York, NY 10110. All rights reserved. AOL now offers free email to everyone. Find out more about what's free from AOL at AOL.com.